ICPT — Intercept Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $793.52m
- $713.07m
- $285.71m
- 57
- 14
- 79
- 49
Annual cashflow statement for Intercept Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | C2020 December 31st | C2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -309 | -345 | -275 | -91.4 | 222 |
| Depreciation | |||||
| Non-Cash Items | 66.8 | 85.1 | 115 | 67.2 | -271 |
| Discontinued Operations | |||||
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -2.85 | 19.3 | -14.8 | -19.7 | 21.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -241 | -237 | -172 | -41.1 | -26.8 |
| Capital Expenditures | -0.167 | -1.14 | -3.89 | -0.397 | -0.568 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -47.9 | -188 | 167 | 71.1 | 262 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -48.1 | -189 | 163 | 70.7 | 262 |
| Financing Cash Flow Items | -2.18 | -2.16 | -1.99 | -1.68 | -0.592 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 264 | 458 | -0.693 | 1.12 | -267 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -26.8 | 31.5 | -9.13 | 28.8 | -38.5 |